skip to main content
Global Search Configuration
  • Close Icon

Refine Results

Clear All








16 Total results for product and free and sample content found


Top 10 Best-Selling Drugs of 2020

02 Jul 2021

Top 10 Best-Selling Drugs of 2020

One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed.

Topic Drug Review Drug Pricing

世界の薬事規制動向&情報を配信, Scrip: 世界の医療用医薬品&製薬産業に関するニュー...

Drug Pricing eBook

13 May 2021

Drug Pricing

Tap into expert coverage of the complex world of drug pricing with insights from analysts at Scrip and Pink Sheet. This eBook includes vital information about issues affecting drug pricing for the US, EU, and other global markets, including patient access, regulatory issues, commercial challenges, value-based pricing, and more.

Topic Drug Pricing

Biomedtracker: 開発中医薬品をFDA承認確率で評価

2021 Clinical Development Success Rates

03 Mar 2021

2021 Clinical Development Success Rates

This is both an updated study of clinical drug development success rates from our 2016 report, and an expansion into the drivers of success with the addition of machine learning modeling to analyze the predictive factors contributing to drug development.

Topic Clinical Trials Drug Development Landscape Drug Pricing


US Drug Pricing Reform Post-Election: Scenarios To Consider And Lessons Learned

18 Nov 2020

US Election Drug Pricing Reform

Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.

Topic US Election 2020 Policy & Regulation Drug Pricing


Biden Administration May Push Rx Pricing To Back Burner With Senate That Stays Pharma Friendly

18 Nov 2020

Biden Administration Rx Pricing

A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry

Topic US Election 2020 Drug Pricing